BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 20, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 4, 2024

View Archived Issues
Amber UI

Amber’s bioelectrical device highly effective in mixed urinary incontinence

Amber Therapeutics Ltd. revealed positive data from the first-in-human investigation of its Amber-UI device, an implantable closed-loop bioelectrical therapy for urinary incontinence. Initial results highlight the safety and scalability of the Amber-UI therapy, which has the potential to meaningfully improve quality of life for patients dealing with the condition. Read More

US FDA seeks adcom illumination on Lumicell imaging drug

The March 5 meeting of the U.S. FDA’s Medical Imaging Drugs Advisory Committee could be the gateway to the first approved intraoperative technology for use in breast cancer that directly examines the lumpectomy cavity for residual cancer. Read More
Illustration of tau proteins in Alzheimer's disease

U.S. first: Neurocode launches Alzpath Alzheimer’s blood test

Neurocode USA Inc. added Alzpath Dx, a blood test for Alzheimer’s disease screening, to its lab developed tests, making it the first available for commercial use in the U.S. The move stands to make screening for the neurodegenerative disease much more accessible, as recent study results indicate Alzpath’s accuracy rivals PET scans and cerebrospinal fluid tests, the current gold standards, in detecting the signature biomarkers of the disease. Read More
Global market charts

FDA’s small business registration fee waiver hinges on bankruptcy

The U.S. FDA has proposed an update to an existing program for user fee reductions for companies grossing less than $100 million, although this latest update is much stingier than that. The update would provide registration fee relief for entities with revenues of $1 million or less, but only if that business is in bankruptcy proceedings, a meager bit of relief considering that registration fees in fiscal 2024 run to less than $7,700. Read More
Cross section illustration of Helix device in heart

Biocardia phase III bolsters cell therapy data in heart failure

While preparing a follow-on phase III study of its Cardiamp cell therapy, Biocardia Inc. has mined positive interim data at a mean 20-month follow-up of all patients in the original Cardiamp HF Trial. Read More
Shiratronics neurostimulation device

Shiratronics reduces risk for antimigraine neurostimulator implant

Shiratronics Inc. seeks patent protection for a rechargeable subcutaneous neurostimulator implant and a method for managing heat during recharge of its battery from an external device and headset. Read More

Med-tech gainers and losers for Feb. 26-March 1, 2024

The top 10 med-tech stock gainers and losers for the week. Read More
DNA with bar chart

Explore BioWorld’s comprehensive infographics collection

Discover a wealth of industry insights with BioWorld’s extensive collection of infographics, covering the latest trends and developments in both biopharma and med-tech. Our weekly infographics are curated to provide concise summaries of key topics: financings (IPOs, private financings, public/other and follow-on offerings), deals and M&As (top deals, and monthly value and volume), regulatory (including U.S. FDA and worldwide approvals), clinical trials and more. In addition, you’ll find access to BioWorld’s year-in-review reports, as well as special infographics about obesity, pain and addiction, biosimilars and the aging space. Read More

Appointments and advancements for Mar. 4, 2024

New hires and promotions in the med-tech industry, including: B. Braun, Convergent Therapeutics, Cytovale, Koneska, VGXI. Read More

Financings for Mar. 4, 2024

Med-tech firms raising money in public or private financings, including: Cryocloud, Envoy Medical, Phagenesis, Shape Memory. Read More

In the clinic for Mar. 4, 2024

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biocardia, Carthera, Mediview. Read More

Other news to note for Mar. 4, 2024

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arteraai, Becton Dickinson, Bone Biologics, Clinical Microbiomics, DNASense, Cytomed, Diacarta Inc., Isightec, Nonagen Bioscience. Read More

Regulatory actions for Mar. 4, 2024

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Diasorin, EDAP TMS, Medtronic. Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • MRI image brain on black background

    ADPD 2026: Can we prevent dementia? Scientists quantify it

    BioWorld
    Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing